Jeffrey Walch
Stock Analyst at Bernstein
(1.95)
# 3,179
Out of 4,455 analysts
13
Total ratings
50%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Buy | 2,630p | $1,983.00 | +32.63% | 1 | Jun 23, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $124 | $123.52 | +0.39% | 1 | Jun 23, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Sell | $7.7 → $9.8 | $14.01 | -30.05% | 3 | Jun 21, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $230.02 | -0.44% | 2 | Jun 8, 2026 | |
| RVMD Revolution Medicines | Maintained: Hold | $151 | $182.08 | -17.07% | 2 | Jun 7, 2026 | |
| BNTX BioNTech SE | Maintained: Hold | $96 | $91.22 | +5.24% | 2 | Jun 4, 2026 | |
| INCY Incyte | Initiated Coverage: Hold | $99 | $113.75 | -12.97% | 1 | May 21, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $221 | $168.52 | +31.14% | 1 | May 21, 2026 |
GSK plc
Jun 23, 2026
Maintained: Buy
Price Target: 2,630p
Current: $1,983.00
Upside: +32.63%
Nuvalent
Jun 23, 2026
Downgraded: Hold
Price Target: $124
Current: $123.52
Upside: +0.39%
Summit Therapeutics
Jun 21, 2026
Reiterated: Sell
Price Target: $7.7 → $9.8
Current: $14.01
Upside: -30.05%
Jazz Pharmaceuticals
Jun 8, 2026
Reiterated: Hold
Price Target: $229
Current: $230.02
Upside: -0.44%
Revolution Medicines
Jun 7, 2026
Maintained: Hold
Price Target: $151
Current: $182.08
Upside: -17.07%
BioNTech SE
Jun 4, 2026
Maintained: Hold
Price Target: $96
Current: $91.22
Upside: +5.24%
Incyte
May 21, 2026
Initiated Coverage: Hold
Price Target: $99
Current: $113.75
Upside: -12.97%
Neurocrine Biosciences
May 21, 2026
Initiated Coverage: Buy
Price Target: $221
Current: $168.52
Upside: +31.14%